SN.L vs VCEL
SN.L: A global medical technology leader focused on restoring patient mobility through advanced orthopedic, sports medicine, and wound care solutions. VCEL: Vericel is a commercial-stage biotechnology company that develops and markets autologous cell therapies for the treatment of severe burns and cartilage damage in the knee.
Side-by-side fundamentals
| Metric | SN.L | VCEL | Edge |
|---|---|---|---|
| Price | £10.19 | $40.05 | |
| Market cap as of 2026-07-24 (share count; price 2026-10-08) | n/a | $2.1B | |
| P/E as of 2026-10-08 | n/a | 95.88 | |
| Net margin | +10.1% | +6.0% | SN.L higher |
| Gross margin | +68.0% | +74.4% | VCEL higher |
| Operating margin FY2025, SEC XBRL | n/a | +4.0% | |
| ROE | +11.8% | +4.7% | SN.L higher |
| ROA FY2025, SEC XBRL | n/a | +3.4% | |
| Debt / equity as of 2026-09-02 | n/a | 0.00 | |
| Revenue growth (YoY) as of 2026-09-02 | n/a | +22.9% | |
| Revenue CAGR (3y) SEC XBRL | n/a | +18.9% | |
| Dividend streak (yrs) SEC XBRL | n/a | 0 | |
| Beta as of 2026-09-02 | n/a | 1.11 | |
| 1-year return | -23.8% | +17.3% | VCEL higher |
Fundamentals: SEC XBRL company filings and annual report filings for the figures marked with a fiscal year, and market data, as of 2026-09-02 for the rest. Filings: SEC EDGAR. Prices are delayed daily-close data.
Last updated 2026-10-07.
Informational only — NOT financial advice. All figures are delayed daily-close data from SEC EDGAR & market data, shown with their as-of date; "Edge" cells are a pure numeric comparison, not a recommendation.